The latest biotech news

News and Trends 4 Mar 2016

Biotech of the week: Solvo, an Efficient Drug Transportation Solution in Hungary

This week, we leave the charming landscapes of southern France and head up to the East. In Budaörs, a suburban city located near Budapest, Hungary’s capital, is where SOLVO, our Biotech of the Week, is located. City: Budders (Budapest), Hungary Founded: 1999 Employees: 80 Financial Data: N/A CEO: Ernő Duda Mission: Solvo Biotechnology’s line of work focuses on the […]

March 4, 2016 - 2 minutesmins - By Joachim Eeckhout

rheumatoid arthritis sirukumab galapagos johnson johnson JJ abbvie

News and Trends 3 Mar 2016

Why is J&J getting rid of Galapagos’ shares, when Everyone else is Buying?

J&J has sold over 2 million of Galapagos‘ shares, which had been inherited from previous acquisitions, reducing its equity in this Belgian Biotech to below 5%. What’s wrong? Back in May, we talked about how J&J and AbbVie could be entering a fight for Galapagos’ filgotinib, a drug for rheumatoid arthritis (RA) that performed well […]

March 3, 2016 - 2 minutesmins - By Denise Neves Gameiro

redhill biopharma israel gastrointestinal crohns cancer pancreatic rhb 104

News and Trends 3 Mar 2016

This Leading Israeli Biopharma is in Good Shape to fight Crohn’s Disease

RedHill Biopharma (Israel) is in a solid financial position to reap the benefits of several advanced trials in inflammatory gastrointestinal diseases, including Crohn’s. The company just released its financial statements, with some interesting highlights… Based in Tel-Aviv, RedHill is developing small molecule oral drugs for a variety of conditions connected to the gastrointestinal tract. It is listed […]

March 3, 2016 - 3 minutesmins - By Denise Neves Gameiro

autism spectrum disorder seaside therapeutics asd fragile x biotech

News and Trends 3 Mar 2016

Reviewing Autism: Can Biotech open up New Horizons?

While Autism Spectrum Disorders (ASD) affect approximately one in 68 children, this hasn’t provoked much enthusiasm among pharmaceutical companies to develop drugs. However, recent advances in basic research Autism and novel gene-editing technologies may boost ASD drug development. The reasons for low interest are a poor understanding of the biological mechanisms underlying Autism Spectrum Disorder, the […]

March 3, 2016 - 6 minutesmins - By Ekaterina Perets

leukemia mesothelioma myeloma sellas cancer immunoncology fda wt1

News and Trends 2 Mar 2016

Swiss Cancer Vaccine Gets 2 FDA Orphan Drug Designations

Sellas (Switzerland) is developing an immunotherapeutic cancer vaccine – which can be easier now that the FDA granted it Orphan Drug designations for two types of cancer (for the lung area and a type of leukemia). Sellas is a biopharma developing treatments for different cancers and diseases of the central nervous system (CNS). Its lead […]

March 2, 2016 - 3 minutesmins - By Denise Neves Gameiro

win horizon centauri antibody avvinity cancer alphamer

News and Trends 2 Mar 2016

New Joint Venture to Shake Up Immuno-Oncology in the UK

Avvinity Therapeutics is the new child of two UK Biotechs: Horizon Discovery and Centauri. The goal? To create the ultimate immuno-oncology toolbox with€32M. Just created, Avvinity is a joint venture targeting the immuno-oncology field, which is worth around €32M – and is only expected to grow. The biotechnological approach to cancer treatments has many Pharma and Biotech companies interested, […]

March 2, 2016 - 3 minutesmins - By Denise Neves Gameiro

syngenta hong kong china monsanto biotech agribusiness

News and Trends 2 Mar 2016

Chinese Chemical Giant moves closer to buy Swiss Syngenta for €39.5Bn

Following Monsanto’s failed second attempt to merge with Syngenta, the Chinese seems to have better luck swaying this European chemical giant. Now ChemChina has its looking to secure a multi-billion loan facility for the acquisition. Syngenta is a well known agribusiness leader in agriculture and seeds production. This Swiss agro-tech was born in 2000 after the merger […]

March 2, 2016 - 2 minutesmins - By Joachim Eeckhout

News and Trends 1 Mar 2016

Artificial Hearts are one Step Closer to the Market with €50M in Funding

Carmat (France) has raised €50M from private investors (dwarfing its 2015’s €3M reserves) in order to further develop its artificial hearts during 2016 and apply for CE Marking. This French Medtech company is developing an artificial heart (one of top examples of futuristic cyborg-like technologies in biotech) that could help patients with end-stage biventricular heart failure. There are people […]

March 1, 2016 - 2 minutesmins - By Denise Neves Gameiro

exelixis ipsen cancercabozantinib renal liver endometrial nsclc

News and Trends 1 Mar 2016

French Ipsen closes €700M deal for Californian Cancer Drug

Ipsen is paying Exelixis $200M upfront, plus $545M in future milestones to acquire commercialization rights for a multi-organ cancer candidate outside US, Canada and Japan. California-based Exelixis has found an European partner to license the small molecule drug, cabozantinib. Ipsen, a French biotech group, will have comercialization rights for cabozantinib worldwide, except in the US and […]

March 1, 2016 - 2 minutesmins - By Denise Neves Gameiro

News and Trends 1 Mar 2016

Overcoming the Challenges of Text-Mining in Biotech Research

A few weeks ago we introduced you to the concept of text-mining in Biotech through this article. Now that you’re more familiar with the concept, let’s ‘mine’ a bit into the current challenges in this field and how to overcome them. Data produced through Biotech research grows with an incredible rate. Everyday, scientists are finding […]

March 1, 2016 - 4 minutesmins - By Jerome Topsent

News and Trends 1 Mar 2016

Here’s why this leading EU Investor turned to NASH

Akarna Therapeutics (US & UK) just raised $15M (€13M) in a series B round led by Forbion Partners – one of the leading VCs from Europe. Also run by existing New York investors New Science Ventures and Third Point, the round purpose was to raise funding to develop a new drug for the liver disease Non-alcoholic steatohepatitis (NASH). I […]

March 1, 2016 - 4 minutesmins - By Philip Hemme

News and Trends 29 Feb 2016

Our Top 5 Articles on Biotech & Rare Disease

Today is Rare Disease Day 2016. Because it is an important field for Biotech, we went back to review some of our best articles on the topic from the Labiotech archives. Here are some of our best – in addition to an overview of 7 Rare diseases and who in Biotech is working on them. Nº […]

February 29, 2016 - 2 minutesmins - By Denise Neves Gameiro

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

Biotech of the week: Solvo, an Efficient Drug Transportation Solution in Hungary

Why is J&J getting rid of Galapagos’ shares, when Everyone else is Buying?

This Leading Israeli Biopharma is in Good Shape to fight Crohn’s Disease

Reviewing Autism: Can Biotech open up New Horizons?

Swiss Cancer Vaccine Gets 2 FDA Orphan Drug Designations

New Joint Venture to Shake Up Immuno-Oncology in the UK

Chinese Chemical Giant moves closer to buy Swiss Syngenta for €39.5Bn

Artificial Hearts are one Step Closer to the Market with €50M in Funding

French Ipsen closes €700M deal for Californian Cancer Drug

Overcoming the Challenges of Text-Mining in Biotech Research

Here’s why this leading EU Investor turned to NASH

Our Top 5 Articles on Biotech & Rare Disease

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!